PD, control, RBD Baseline → PD, control, RBD 18/12 → PD, control, RBD 36/12 → PD, control, RBD: 18/12 FU from 54/12 to max 180/12

OPDC2: 2015-2020
OPDC3: 2021-2026

OPDC1: 2015-2020

Oct 2015 PD recruitment STOPS

Ongoing new RBD and RBD to PD convertor recruitment

316 At-risk

1096 Baseline PD

320 Controls

Patient spouses

Within 3.5 years of PD diagnosis

111 First degree relatives

LRRK 2/GBA +ve and gene –ve 1st degree relatives

280 PSG-diagnosed RBD

Oxford/Papworth/Sheffield sleep clinics

PD inclusion criteria: Clinically probable PD (UKPDBB), within 3.5 years of diagnosis, NINDS screening tool for atypical features

Motor/Clinical/Demographic- all

MDS-UPDRS I-IV, Hoehn and Yahr, Purdue Pegboard, 3 metre TUG, flamingo 30 sec test, Purdue Pegboard, BP/P (lying & 3minute standing), height, weight, ethnicity, social background, past medical and family history, environmental questionnaire, drug history, smoking/alcohol history, presenting PD features, Family History, PD meds, clinical CGI, LEDD, previous medication exposure, PD diagnostic probability, Freezing of Gait Q'aire (FOG), PD screening Q'aire, Activity and Fatigue Questionnaires (subgroup).

Non-Motor/ADL- all

Schwab and England, 16-item Sniffin Odor Identification Sticks, Constipation Q'aire, Big Five Personality Inventory, Epworth Sleep Scale, RBDSQ'aire, EQ-5D, HADS, Beck Depression Inventory-II, QUIP-current-short, Big Five Inventory (BFI)

Cognitive Function- all

MMSE, Montreal Cognitive Assessment, Phonemic/Semantic category fluency, NART, IQ-CODE, FAQ (subgroup)

Wet biomarkers:
DNA, serum (all, each visit); plasma, skin biopsy, CSF (subgroup only, selected visits)

Digital (PD, RBD, control subgroup): OPDC smartphone motor test, Axivity device free-living gait, home-PSG overnight recordings, web-based cognitive testing

Imaging (PD, RBD and control subgroup): MRI and DaT SPECT baseline/longitud